Cost-effectiveness of Rosiglitazone Combination Therapy for the Treatment of Type 2 Diabetes Mellitus in the UK

被引：0
|
作者：
Sophie Beale
Adrian Bagust
Arran T. Shearer
Alan Martin
Lisa Hulme
机构：
[1] University of York,York Health Economics Consortium, Market Square
[2] University of Liverpool,The University of Liverpool Management School
[3] GlaxoSmithKline,UK Health Outcomes
[4] GlaxoSmithKline,Global Health Outcomes
来源：
PharmacoEconomics | 2006年 / 24卷 / Suppl 1期
关键词：
Metformin; National Health Service; Rosiglitazone; Glycaemic Control; Sulfonylurea;
D O I：
10.2165/00019053-200624001-00003
中图分类号：
学科分类号：
摘要：
Introduction: Recent clinical trial results have demonstrated that, in patients with type 2 diabetes, second-line treatment of rosiglitazone in combination with metformin can lead to significant improvements in the control of fasting plasma glucose/glycosylated haemoglobin A1c (HbA1c) after the failure of metformin monotherapy. Our objective was to assess the cost-effectiveness of the use of rosiglitazone in combination with metformin in overweight and obese patients with type 2 diabetes in the UK, failing to maintain glycaemic control with metformin monotherapy compared with conventional care using metformin in combination with sulfonylurea.
引用
下载
收藏
页码：21 / 34
页数：13
相关论文
共 50 条
  • [21] Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation
    Czoski-Murray, C
    Warren, E
    Chilcott, J
    Beverley, C
    Psyllaki, MA
    Cowan, J
    HEALTH TECHNOLOGY ASSESSMENT, 2004, 8 (13) : 1 - +
  • [22] The cost-effectiveness of intensive therapy for diabetes mellitus
    Herman, WH
    Dasbach, EJ
    Songer, TJ
    Eastman, RC
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1997, 26 (03) : 679 - +
  • [23] Screening for type 2 diabetes mellitus: A cost-effectiveness analysis
    Hoerger, TJ
    Harris, R
    Hicks, KA
    Donahue, K
    Sorensen, S
    Engelgau, M
    ANNALS OF INTERNAL MEDICINE, 2004, 140 (09) : 689 - 699
  • [24] US Cost-Effectiveness of Saxagliptin in Type 2 Diabetes Mellitus
    Bergenheim, Klas
    Williams, Setareh A.
    Bergeson, Joette Gdovin
    Stern, Lee
    Sriprasert, Michelle
    AMERICAN JOURNAL OF PHARMACY BENEFITS, 2012, 4 (01) : 20 - 28
  • [25] DRIVERS OF COST-EFFECTIVENESS IN TYPE-2 DIABETES MELLITUS
    McEwan, P.
    Foos, V
    Grant, D.
    Lamotte, M.
    Palmer, J. L.
    Lloyd, A.
    VALUE IN HEALTH, 2013, 16 (03) : A165 - A165
  • [26] COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN IN THE TREATMENT OF TYPE-2 DIABETES MELLITUS IN SPAIN
    Capel, M.
    Pomares, E.
    Perez-Alcantara, F.
    Simon, S.
    VALUE IN HEALTH, 2020, 23 : S508 - S508
  • [27] Cost-effectiveness of rosiglitazone for treatment of type 2 diabetes in Portugal using different methods to model clinical
    Taylor, M. J.
    Bagust, A.
    Pereira, J. A.
    Mendes da Costa, S.
    Beale, S.
    Shearer, A.
    VALUE IN HEALTH, 2006, 9 (06) : A232 - A232
  • [28] COST-EFFECTIVENESS OF FIXED-DOSE COMBINATION (FDC) OF VILDAGLIPTIN/METFORMIN FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2 IN MEXICO
    Lemus, A.
    Jimenez Aranda, P.
    VALUE IN HEALTH, 2013, 16 (07) : A689 - A689
  • [29] Cost-effectiveness of non-surgical periodontal therapy for patients with type 2 diabetes in the UK
    Solowiej-Wedderburn, Josephine
    Ide, Mark
    Pennington, Mark
    JOURNAL OF CLINICAL PERIODONTOLOGY, 2017, 44 (07) : 700 - 707
  • [30] COST-EFFECTIVENESS OF DAPAGLIFLOZIN COMPARED TO DPP-4 INHIBITORS AS TRIPLE THERAPY IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS FROM A UK HEALTH CARE PERSPECTIVE
    Charokopou, M.
    Vioix, H.
    Eddowes, L. A.
    Griffiths, M.
    Verheggen, B. G.
    Gabriel, Z.
    Tolley, K.
    VALUE IN HEALTH, 2014, 17 (07) : A347 - A347
12345